Table 1. Baseline patient demographics and disease characteristics.
| Baseline characteristic | Ridaforolimus (N=45) |
|---|---|
|
Age (years) | |
| Mean (s.d.) | 66.1 (10.4) |
| Median | 66.7 |
| Range |
28–89 |
|
ECOG performance status, n (%) | |
| 0 | 30 (67) |
| 1 | 13 (29) |
| 2 |
2 (4) |
|
Tumour histology, n (%) | |
| Endometrioid | 28 (62) |
| Papillary serous | 10 (22) |
| Mixed epithelial | 1 (2) |
| Carcinosarcoma or MMMT |
5 (11) |
|
Location or organ with metastatic disease, n (%)a | |
| Lymph nodes | 25 (56) |
| Lung | 23 (51) |
| Liver | 13 (29) |
| Other | 13 (29) |
| Vagina | 6 (13) |
| Ascites (non-measurable) | 6 (13) |
| Peritoneum |
5 (11) |
|
Prior treatment, n (%) | |
| Chemotherapy regimens | |
| 1 | 14 (31) |
| 2 | 26 (58) |
| 3 or more | 3 (7) |
| Missing | 2 (4) |
| Radiotherapy | 30 (67) |
| Surgical therapy | 44 (98) |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; MMMT=malignant mixed Müllerian tumour; s.d.=standard deviation.
a
Percentages may add up to more than 100%, as a patient may have more than one site of disease.